English | 简体中文 | 繁體中文 | 한국어
Share:
Bavarian Nordic to Host First Quarter 2018 Results Conference Call

COPENHAGEN, Denmark - May 16, 2018 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
SeaBird Exploration: SeaBird received extension to current OBN survey in US Gulf of Mexico  
Oct 15, 2018 09:00 ET
Klövern AB (publ): Klövern considers issue of hybrid bonds  
Oct 15, 2018 08:30 ET
Amer Sports third quarter 2018 results published on October 25  
Oct 15, 2018 08:00 ET
ABN AMRO press release: Pre-closing announcements  
Oct 15, 2018 08:00 ET
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research  
Oct 15, 2018 07:05 ET
INGREDION TO RELEASE 2018 THIRD-QUARTER FINANCIAL RESULTS AND HOLD CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 1, 2018  
Oct 11, 2018 22:29 ET
Eastman Schedules Third-Quarter 2018 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast  
Oct 4, 2018 22:29 ET
JCPenney Launches Peyton and Parker,(TM) a New Private Brand Designed for Families and Socially Connected Moms  
Oct 2, 2018 22:29 ET
Lubrizol and Danquinsa Feature High-Performing Bonding Solutions and Non-Yellowing TPUs at Fakuma 2018  
Sept 26, 2018 21:59 ET
INGREDION ANNOUNCES $60 MILLION OF INCREMENTAL PLANNED SPECIALTY CAPITAL INVESTMENTS IN ASIA-PACIFIC; Company's latest move expands its capacity for higher-value specialty ingredients  
Sept 26, 2018 21:29 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: